This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
inflammatory syndrome | 291 |
multisystem inflammatory | 277 |
kawasaki disease | 140 |
coronavirus disease | 125 |
pediatric patients | 85 |
acute respiratory | 76 |
case series | 65 |
coronary artery | 64 |
severe covid | 60 |
systematic review | 52 |
united states | 51 |
respiratory syndrome | 49 |
new york | 49 |
severe acute | 47 |
intensive care | 46 |
temporally associated | 44 |
cardiac involvement | 43 |
shock syndrome | 42 |
cytokine storm | 42 |
clinical characteristics | 41 |
syndrome coronavirus | 39 |
pediatric covid | 39 |
novel coronavirus | 37 |
syndrome temporally | 36 |
cohort study | 35 |
cardiac dysfunction | 35 |
inflammatory markers | 35 |
respiratory distress | 33 |
clinical presentation | 33 |
hyperinflammatory shock | 31 |
heart failure | 30 |
toxic shock | 30 |
imaging findings | 30 |
inflammatory multisystem | 29 |
like disease | 29 |
intravenous immunoglobulin | 29 |
immune response | 29 |
doc id | 28 |
clinical features | 28 |
cord uid | 28 |
reactive protein | 28 |
multisystem syndrome | 28 |
distress syndrome | 26 |
pediatric population | 25 |
hospitalized patients | 25 |
gastrointestinal symptoms | 24 |
macrophage activation | 23 |
rights reserved | 23 |
disease control | 23 |
task force | 22 |
respiratory failure | 22 |
care unit | 21 |
immune system | 21 |
associated multisystem | 21 |
observational cohort | 21 |
respiratory symptoms | 21 |
abdominal pain | 21 |
pediatric intensive | 21 |
activation syndrome | 20 |
previously healthy | 20 |
immune responses | 19 |
pediatric inflammatory | 19 |
ng ml | 19 |
critically ill | 19 |
severe disease | 18 |
left ventricular | 18 |
natriuretic peptide | 18 |
risk factors | 18 |
viral load | 17 |
mechanical ventilation | 17 |
among children | 17 |
acute heart | 17 |
severe illness | 17 |
less severe | 17 |
ventricular dysfunction | 17 |
severe kawasaki | 17 |
mg kg | 17 |
york city | 17 |
erythrocyte sedimentation | 16 |
respiratory tract | 16 |
pg ml | 16 |
case report | 16 |
york state | 16 |
social distancing | 15 |
italian epicentre | 15 |
observational study | 15 |
case reports | 15 |
healthy children | 15 |
polymerase chain | 15 |
world health | 15 |
sedimentation rate | 15 |
elevated inflammatory | 15 |
health organization | 15 |
acute phase | 15 |
ejection fraction | 15 |
chain reaction | 15 |
mg dl | 14 |
system inflammatory | 14 |
critical care | 14 |
seasonal hcovs | 14 |
acute kidney | 14 |
artery dilation | 14 |
less likely | 14 |
data collection | 14 |
cytokine release | 14 |
global sars | 14 |
peer review | 14 |
following sars | 14 |
paediatric multisystem | 14 |
artery aneurysms | 14 |
adult covid | 14 |
case definition | 14 |
syndrome related | 14 |
kidney injury | 14 |
children presenting | 13 |
hemophagocytic lymphohistiocytosis | 13 |
severe cases | 13 |
vertical transmission | 13 |
severe respiratory | 13 |
ill children | 13 |
organ dysfunction | 13 |
granted medrxiv | 13 |
reported cases | 13 |
author funder | 13 |
immune dysregulation | 13 |
coronavirus infection | 13 |
young children | 13 |
laboratory evidence | 13 |
upper respiratory | 13 |
medical information | 13 |
systolic function | 12 |
treated patients | 12 |
infectious disease | 12 |
children may | 12 |
infectious diseases | 12 |
inflammatory disease | 12 |
viral infection | 12 |
laboratory findings | 12 |
emergency department | 12 |
pediatric cases | 12 |
positive sars | 12 |
confirmed cases | 12 |
higher risk | 12 |
systemic inflammation | 12 |
copyright holder | 12 |
care units | 12 |
posted june | 11 |
type natriuretic | 11 |
laboratory markers | 11 |
disease severity | 11 |
asymptomatic children | 11 |
term management | 11 |
myocardial dysfunction | 11 |
clinical manifestations | 11 |
hyperinflammatory syndrome | 11 |
version posted | 11 |
inflammatory response | 11 |
mis medis | 11 |
ventricular function | 11 |
confirmed covid | 11 |
mucosal changes | 11 |
heart disease | 11 |
physical activity | 10 |
blood cell | 10 |
like multisystem | 10 |
reuse allowed | 10 |
median age | 10 |
informed consent | 10 |
many patients | 10 |
septic shock | 10 |
organ systems | 10 |
like illness | 10 |
allowed without | 10 |
without permission | 10 |
health professionals | 10 |
neuropsychiatric symptoms | 10 |
hospitalized children | 10 |
pediatric multisystem | 10 |
acute myocarditis | 10 |
clinical symptoms | 10 |
magnetic resonance | 10 |
cardiac injury | 10 |
organ involvement | 10 |
increased risk | 10 |
scientific statement | 10 |
hospital day | 10 |
thoracic imaging | 10 |
diagnostic criteria | 9 |
clinical course | 9 |
retrospective cohort | 9 |
converting enzyme | 9 |
atypical kawasaki | 9 |
seasonal coronaviruses | 9 |
release syndrome | 9 |
pediatric mis | 9 |
small number | 9 |
health care | 9 |
standard deviation | 9 |
extracorporeal membrane | 9 |
diagnostic evaluation | 9 |
organ system | 9 |
pandemic multisystem | 9 |
oropharyngeal swabs | 9 |
immunomodulatory treatment | 9 |
child health | 9 |
necrosis factor | 9 |
paediatric inflammatory | 9 |
prospective observational | 9 |
without rash | 9 |
cardiogenic shock | 9 |
membrane oxygenation | 9 |
neutralizing activity | 9 |
artery aneurysm | 9 |
patients infected | 9 |
cardiac manifestations | 9 |
glass opacities | 9 |
young adults | 9 |
cardiac mri | 9 |
mental health | 8 |
clinical signs | 8 |
different clinical | 8 |
immune suppression | 8 |
system involvement | 8 |
neutralizing antibodies | 8 |
like lesions | 8 |
platelet count | 8 |
hyperinflammatory state | 8 |
ill patients | 8 |
dose aspirin | 8 |
patients without | 8 |
authors declare | 8 |
met criteria | 8 |
clinical trials | 8 |
novel virus | 8 |
acute pediatric | 8 |
lactate dehydrogenase | 8 |
positive rt | 8 |
lower respiratory | 8 |
mimicking kawasaki | 8 |
may also | 8 |
resonance imaging | 8 |
proinflammatory cytokines | 8 |
cell count | 8 |
elevated levels | 8 |
vast majority | 8 |
gene expression | 8 |
receptor antagonist | 8 |
blood pressure | 8 |
novel case | 8 |
united kingdom | 8 |
acute cardiac | 8 |
neonates born | 8 |
children diagnosed | 8 |
information system | 8 |
tumor necrosis | 8 |
respiratory disease | 8 |
lv dysfunction | 8 |
seasonal hcov | 7 |
initial reports | 7 |
mucocutaneous manifestations | 7 |
tracheal aspirates | 7 |
one patient | 7 |
epidemiological characteristics | 7 |
typical pediatric | 7 |
kg day | 7 |
adult patients | 7 |
systemic hyperinflammation | 7 |
second dose | 7 |
liver function | 7 |
milder cases | 7 |
term outcomes | 7 |
cardiac imaging | 7 |
possible causes | 7 |
public health | 7 |
nervous system | 7 |
antibody responses | 7 |
infection admitted | 7 |
years old | 7 |
complete blood | 7 |
medical conditions | 7 |
coronary arteries | 7 |
viral loads | 7 |
data interpretation | 7 |
supportive care | 7 |
laboratory values | 7 |
disease shock | 7 |
affected children | 7 |
viral transmission | 7 |
expert opinion | 7 |
less frequent | 7 |
urgent care | 7 |
confirmed sars | 7 |
chest radiographs | 7 |
mildly symptomatic | 7 |
american heart | 7 |
white blood | 7 |
inflammatory cytokines | 7 |
canadian pediatric | 7 |
treatment guidelines | 7 |
future studies | 7 |
respiratory viruses | 7 |
mortality rate | 7 |
systemic inflammatory | 7 |
respiratory infection | 7 |
gi symptoms | 7 |
early infection | 7 |
patients may | 7 |
persistent fever | 7 |
preliminary report | 7 |
children aged | 7 |
may help | 7 |
recent sars | 7 |
systematic reviews | 7 |
age group | 7 |
african american | 7 |
single center | 7 |
congenital heart | 7 |
sample collection | 7 |
infection control | 7 |
symptomatic infection | 6 |
maternal sars | 6 |
mean age | 6 |
cardiovascular disease | 6 |
weight heparin | 6 |
reports suggest | 6 |
severe symptoms | 6 |
artery abnormalities | 6 |
social contacts | 6 |
overlapping features | 6 |
disease pathogenesis | 6 |
least one | 6 |
may explain | 6 |
blood count | 6 |
artery dilatation | 6 |
function tests | 6 |
oral mucosal | 6 |
multicenter study | 6 |
platelet counts | 6 |
mucocutaneous disease | 6 |
healthcare providers | 6 |
previously reported | 6 |
study design | 6 |
storm syndrome | 6 |
infected children | 6 |
samples collected | 6 |
viral infections | 6 |
elevated troponin | 6 |
coronary aneurysms | 6 |
immunological features | 6 |
assessment tool | 6 |
coronary involvement | 6 |
immunomodulatory therapy | 6 |
inclusion criteria | 6 |
ab responses | 6 |
multisystem organ | 6 |
interquartile range | 6 |
accepted article | 6 |
requiring hospitalization | 6 |
better understanding | 6 |
children covid | 6 |
respiratory support | 6 |
respiratory syncytial | 6 |
heart association | 6 |
adult population | 6 |
center experience | 6 |
two patients | 6 |
human coronavirus | 6 |
many children | 6 |
children years | 6 |
better prognosis | 6 |
cervical lymphadenopathy | 6 |
immediately stored | 6 |
convalescent plasma | 6 |
multicentre cohort | 6 |
specimen collection | 6 |
computed tomography | 6 |
vital signs | 6 |
syncytial virus | 6 |
patients will | 6 |
less frequently | 6 |
myocardial involvement | 6 |
factors associated | 6 |
erythema multiforme | 6 |
lessons learned | 6 |
pcr testing | 6 |
fluid resuscitation | 6 |
data regarding | 6 |
health center | 6 |
first case | 6 |
ventricular systolic | 6 |
patients presenting | 6 |
significantly elevated | 6 |
mucocutaneous findings | 6 |
north america | 6 |
narrative review | 6 |
available data | 6 |
pulmonary emboli | 6 |
american college | 6 |
sore throat | 6 |
clinical team | 6 |
severe course | 6 |
underlying medical | 6 |
cystic fibrosis | 6 |
thrombotic complications | 6 |
mental status | 6 |
innate immune | 6 |
molecular weight | 6 |
troponin levels | 6 |
pediatric critical | 6 |
low molecular | 6 |
contact tracing | 6 |
one death | 6 |
information systems | 6 |
age range | 6 |
incomplete kd | 6 |
typical acute | 6 |
existing medical | 6 |
kd patients | 6 |
children associated | 6 |
severe pulmonary | 5 |
chronic disease | 5 |
seropositive children | 5 |
profound lymphopenia | 5 |
low dose | 5 |
inotropic support | 5 |
induced kawasaki | 5 |
provide guidance | 5 |
central nervous | 5 |
response may | 5 |
children will | 5 |
conduction abnormalities | 5 |
shed light | 5 |
previously described | 5 |
laboratory results | 5 |
children shows | 5 |
clinical presentations | 5 |
chronic patients | 5 |
lower platelet | 5 |
dysfunction markers | 5 |
secondary hemophagocytic | 5 |
systolic dysfunction | 5 |
epidemiological study | 5 |
myocardial damage | 5 |
may contribute | 5 |
natural killer | 5 |
new england | 5 |
high levels | 5 |
juvenile idiopathic | 5 |
reported patients | 5 |
severe manifestations | 5 |
reverse transcriptase | 5 |
will need | 5 |
aleksandar milenkovic | 5 |
syndrome associated | 5 |
proposed management | 5 |
skin findings | 5 |
factors driving | 5 |
novel multisystem | 5 |
infect dis | 5 |
acute covid | 5 |
confirmed pediatric | 5 |
acute myocardial | 5 |
supplementary material | 5 |
cardiac magnetic | 5 |
storm syndromes | 5 |
skin lesions | 5 |
fetal development | 5 |
sample size | 5 |
depressed ejection | 5 |
although children | 5 |
icu admission | 5 |
human coronaviruses | 5 |
clinical guidance | 5 |
biorepository will | 5 |
trained immunity | 5 |
worldwide cases | 5 |
quality assessment | 5 |
mild disease | 5 |
common clinical | 5 |
hbss minus | 5 |
global pandemic | 5 |
cdc covid | 5 |
increased incidence | 5 |
thromboembolic complications | 5 |
growing number | 5 |
critical cases | 5 |
laboratory testing | 5 |
multisystem involvement | 5 |
institutional review | 5 |
royal college | 5 |
pediatric acute | 5 |
remains unclear | 5 |
prothrombin time | 5 |
coronary dilation | 5 |
paediatric patients | 5 |
classic kd | 5 |
nk cells | 5 |
centers required | 5 |
viral susceptibility | 5 |
children affected | 5 |
disease burden | 5 |
high viral | 5 |
less vigorous | 5 |
four seasonal | 5 |
cardiac markers | 5 |
shows milder | 5 |
multiple organ | 5 |
organ failure | 5 |
pulmonary disease | 5 |
major presentation | 5 |
hospital stay | 5 |
conical tube | 5 |
recent study | 5 |
acute infection | 5 |
severe systemic | 5 |
creatine kinase | 5 |
significant difference | 5 |
review board | 5 |
old girl | 5 |
supplemental table | 5 |
idiopathic arthritis | 5 |
retrospective review | 5 |
positive antibodies | 5 |
requiring intensive | 5 |
late april | 5 |
frequently reported | 5 |
cardiac function | 5 |
ct features | 5 |
peripheral blood | 5 |
myocardial injury | 5 |
aged years | 5 |
less commonly | 5 |
inflammatory state | 5 |
table summarizes | 5 |
testing positive | 5 |
severe sars | 5 |
age groups | 5 |
case definitions | 5 |
laboratory data | 5 |
england journal | 5 |
series multisystem | 5 |
hypothetical pathogenesis | 5 |
cardiac features | 5 |
develop mis | 5 |
extremity changes | 5 |
ground glass | 5 |
important lessons | 5 |
studies will | 5 |
medical care | 5 |
may provide | 5 |
response team | 5 |
lymphocyte ratio | 5 |
elevated cardiac | 5 |
high fever | 5 |
chinese center | 5 |
young age | 5 |
laboratory tests | 5 |
suspected covid | 5 |
previous reports | 5 |
oxygen saturation | 5 |
severe coronavirus | 5 |
young adult | 5 |
two investigators | 5 |
study period | 5 |
clinical findings | 5 |
distinct clinical | 5 |
study multisystem | 5 |
novel syndrome | 5 |
demographic data | 4 |
currently available | 4 |
myocardial depression | 4 |
city multisystem | 4 |
inflammatory cascade | 4 |
clinical picture | 4 |
much higher | 4 |
better understand | 4 |
parents guardians | 4 |
severely ill | 4 |
cell disease | 4 |
possible mis | 4 |
existing mis | 4 |
first reported | 4 |
children appear | 4 |
herd immunity | 4 |
pilot grant | 4 |
common symptoms | 4 |
shock related | 4 |
adaptive immune | 4 |
data integrity | 4 |
consider cytokine | 4 |
quality evidence | 4 |
illness requiring | 4 |
clinical data | 4 |
nasal cannula | 4 |
initial presentation | 4 |
infectious cytokine | 4 |
may lead | 4 |
reported data | 4 |
temporal association | 4 |
almost half | 4 |
immune globulin | 4 |
therapeutic anticoagulation | 4 |
children less | 4 |
studies included | 4 |
health emergency | 4 |
health status | 4 |
immune phenotypes | 4 |
similar findings | 4 |
incomplete kawasaki | 4 |
data analysis | 4 |
prospective cohort | 4 |
primary hlh | 4 |
multiorgan involvement | 4 |
patient received | 4 |
patient presenting | 4 |
virus spread | 4 |
alert network | 4 |
help healthcare | 4 |
pandemic continues | 4 |
disease associated | 4 |
present patients | 4 |
springer nature | 4 |
positive patients | 4 |
robust immune | 4 |
hospital protocols | 4 |
lower incidence | 4 |
immunomodulatory therapies | 4 |
prothrombotic coagulopathy | 4 |
commonly used | 4 |
adolescents multisystem | 4 |
family member | 4 |
manuscript writing | 4 |
hemodynamic instability | 4 |
stage iii | 4 |
data capture | 4 |
recently reported | 4 |
rheumatic diseases | 4 |
patient data | 4 |
severe adult | 4 |
patients presented | 4 |
symptom onset | 4 |
healthcare system | 4 |
pediatr doi | 4 |
patients present | 4 |
inflammatory emerging | 4 |
valvular dysfunction | 4 |
will allow | 4 |
prior infections | 4 |
higher rates | 4 |
innate response | 4 |
cutaneous manifestations | 4 |
induced multisystem | 4 |
verifying data | 4 |
several studies | 4 |
cardiac findings | 4 |
children infected | 4 |
journal pre | 4 |
high proportion | 4 |
affecting children | 4 |
immunoglobulin therapy | 4 |
associated pediatric | 4 |
imaging features | 4 |
ml conical | 4 |
funding agencies | 4 |
sickle cell | 4 |
developing mis | 4 |
novel covid | 4 |
laboratory studies | 4 |
standard deviations | 4 |
immunomodulatory effects | 4 |
petar rajkovic | 4 |
commonly reported | 4 |
typical covid | 4 |
pregnant women | 4 |
nasal gene | 4 |
emerging disease | 4 |
cellular injury | 4 |
milder disease | 4 |
elevated ferritin | 4 |
mycoplasma pneumoniae | 4 |
patients vs | 4 |
exponential growth | 4 |
presentation component | 4 |
newborns born | 4 |
children admitted | 4 |
see table | 4 |
many cases | 4 |
recovery trial | 4 |
adolescents temporally | 4 |
coronavirus pandemic | 4 |
six patients | 4 |
possibly due | 4 |
disease following | 4 |
temporally related | 4 |
pediatric viral | 4 |
new coronavirus | 4 |
like hyperinflammatory | 4 |
inflammatory process | 4 |
less common | 4 |
echocardiographic findings | 4 |
blood culture | 4 |
research staff | 4 |
skin rash | 4 |
like features | 4 |
angiotensin converting | 4 |
lymphocyte counts | 4 |
onset infection | 4 |
new syndrome | 4 |
type i | 4 |
neonatal early | 4 |
four weeks | 4 |
named multisystem | 4 |
less severity | 4 |
cardiovascular system | 4 |
infected mothers | 4 |
high incidence | 4 |
million confirmed | 4 |
current evidence | 4 |
approximately one | 4 |
team members | 4 |
covid phenotype | 4 |
respiratory viral | 4 |
old boy | 4 |
risk factor | 4 |
minimally invasive | 4 |
disease progression | 4 |
serology testing | 4 |
delayed development | 4 |
high dose | 4 |
research team | 4 |
childhood disease | 4 |
disease caused | 4 |
clinical care | 4 |
present cohort | 4 |
hyperimmune response | 4 |
renal function | 4 |
vessel vasculitis | 4 |
cardiac biomarkers | 4 |
tested positive | 4 |
uk tertiary | 4 |
cases reported | 4 |
open data | 4 |
thromboplastin time | 4 |
neuropsychiatric manifestations | 4 |
kd guidelines | 4 |
disease complicated | 4 |
reduced mortality | 4 |
one month | 4 |
mild symptoms | 4 |
early phase | 4 |
literature search | 4 |
health alert | 4 |
lymph node | 4 |
invasive mechanical | 4 |
protective immunity | 4 |
patients meeting | 4 |
pediatric infectious | 4 |
humoral responses | 4 |
rna polymerase | 4 |
signs symptoms | 4 |
moderate coronavirus | 4 |
open surgery | 4 |
conjunctival injection | 4 |
respiratory illness | 4 |
results show | 4 |
dermatologic manifestations | 4 |
may include | 4 |
become available | 4 |
critical illness | 4 |
partial thromboplastin | 4 |
dysregulated immune | 4 |
dexmedetomidine drip | 4 |
insufficient data | 4 |
creative commons | 4 |
alternative plausible | 4 |
like syndrome | 4 |
study covid | 4 |
liver injury | 4 |
elevated crp | 4 |
institutional study | 4 |
lower levels | 4 |
early reports | 4 |
states characteristics | 4 |
disease clinical | 4 |
median duration | 4 |
transcriptase polymerase | 4 |
positive children | 4 |
submitted work | 4 |
nasopharyngeal swab | 4 |
study clinical | 4 |
health service | 4 |
brain natriuretic | 4 |
three patients | 4 |
pediatric beds | 4 |
evidence suggests | 4 |
hospital course | 4 |
features similar | 4 |
test positive | 4 |
general population | 4 |
guidance statements | 4 |
term sequelae | 4 |
infected pneumonia | 4 |
virus disease | 4 |
infants born | 4 |
cracked lips | 4 |
fully understood | 4 |
national institutes | 4 |
information regarding | 4 |
older children | 3 |
cell entry | 3 |
ml aliquots | 3 |
classical kd | 3 |
abnormal laboratory | 3 |
neonatal exposure | 3 |
patients affected | 3 |
cases locally | 3 |
treat mis | 3 |
echocardiogram showed | 3 |
july th | 3 |
documented thrombosis | 3 |
sectional studies | 3 |
blood samples | 3 |
testing techniques | 3 |
initial laboratory | 3 |
acute disease | 3 |
categorical variables | 3 |
spectrum antibiotics | 3 |
different points | 3 |
plausible diagnosis | 3 |
highly elevated | 3 |
six days | 3 |
help identify | 3 |
altered inflammatory | 3 |
bilateral peripheral | 3 |
positive covid | 3 |
scientific evidence | 3 |
gadolinium enhancement | 3 |
hyperinflammatory response | 3 |
leukocyte antigen | 3 |
threatening manifestations | 3 |
neurological manifestations | 3 |
guidance document | 3 |
via telephone | 3 |
multiorgan dysfunction | 3 |
strong initial | 3 |
ecmo support | 3 |
pediatric cardiology | 3 |
jurisdictional claims | 3 |
host immune | 3 |
inflammatory diseases | 3 |
alarming rate | 3 |
human leukocyte | 3 |
mesenteric adenitis | 3 |
study id | 3 |
bacterial sepsis | 3 |
direct cellular | 3 |
mapping systemic | 3 |
tract disease | 3 |
cases described | 3 |
patient management | 3 |
high risk | 3 |
limited data | 3 |
antiviral therapy | 3 |
initial treatment | 3 |
multiple case | 3 |
paediatric hospital | 3 |
nonspecific inflammatory | 3 |
multiorgan failure | 3 |
immune cell | 3 |
th may | 3 |
center nis | 3 |
hospitalization rates | 3 |
imaging results | 3 |
specialist examinations | 3 |
china sars | 3 |
approximately half | 3 |
reactive antibodies | 3 |
shlh mas | 3 |
alanine aminotransferase | 3 |
acute early | 3 |
health system | 3 |
novel disease | 3 |
patients tested | 3 |
emergency departments | 3 |
institutional affiliations | 3 |
include direct | 3 |
bone marrow | 3 |
may benefit | 3 |
patients received | 3 |
reports emerged | 3 |
inflammatory agents | 3 |
intravenous immune | 3 |
big data | 3 |
vigorous immune | 3 |
clinical follow | 3 |
distancing measures | 3 |
reported mis | 3 |
clinical deterioration | 3 |
track covid | 3 |
prior infection | 3 |
mild illness | 3 |
chosen physicians | 3 |
staphylococcus aureus | 3 |
ml vs | 3 |
immunocompromised children | 3 |
better characterize | 3 |
household contacts | 3 |
us children | 3 |
inflammatory syndromes | 3 |
central role | 3 |
potential therapies | 3 |
state multisystem | 3 |
aged less | 3 |
medrxiv preprint | 3 |
large case | 3 |
also presented | 3 |
similar hyperinflammatory | 3 |
vasodilatory shock | 3 |
currently unknown | 3 |
four patients | 3 |
infection rates | 3 |
recent months | 3 |
resemble kawasaki | 3 |
states clinical | 3 |
prophylactic anticoagulation | 3 |
executive functioning | 3 |
care medicine | 3 |
multicenter studies | 3 |
paediatric population | 3 |
positive serology | 3 |
absolute lymphocyte | 3 |
clinical judgment | 3 |
emergency use | 3 |
morphologic patterns | 3 |
small percentage | 3 |
kdss patients | 3 |
disease covid | 3 |
lower prevalence | 3 |
chest radiograph | 3 |
stool samples | 3 |
massachusetts general | 3 |
aneurysm formation | 3 |
table i | 3 |
markedly elevated | 3 |
include fever | 3 |
close contact | 3 |
multidisciplinary team | 3 |
kd includes | 3 |
smart healthcare | 3 |
pediatric sars | 3 |
organ damage | 3 |
infected people | 3 |
available evidence | 3 |
future treatment | 3 |
mri images | 3 |
cord blood | 3 |
two entities | 3 |
will continue | 3 |
host response | 3 |
cardiac ventricular | 3 |
patient groups | 3 |
reserved table | 3 |
medical data | 3 |
highly increased | 3 |
picu admission | 3 |
china coronavirus | 3 |
tool published | 3 |
nan doi | 3 |
adjunctive therapy | 3 |
symptoms consistent | 3 |
fulminant myocarditis | 3 |
fold increase | 3 |
possible vertical | 3 |
study found | 3 |
common findings | 3 |
controlled trial | 3 |
sag motif | 3 |
children compared | 3 |
vaccination strategies | 3 |
antiviral therapies | 3 |
scientific brief | 3 |
nature remains | 3 |
bcg vaccination | 3 |
term follow | 3 |
pulmonary phase | 3 |
inflammatory conditions | 3 |
present results | 3 |
giant coronary | 3 |
hospitalized cohort | 3 |
clinical trial | 3 |
pcr negative | 3 |
either acute | 3 |
acid dehydrogenase | 3 |
complex immune | 3 |
may need | 3 |
immunomodulatory agents | 3 |
key words | 3 |
physical distancing | 3 |
managing mis | 3 |
patients diagnosed | 3 |
ferritin ng | 3 |
multisystem inflammation | 3 |
protocols included | 3 |
known entities | 3 |
corticosteroid treatment | 3 |
atrioventricular block | 3 |
ab profile | 3 |
least days | 3 |
milder symptoms | 3 |
provide insight | 3 |
significantly higher | 3 |
phase trial | 3 |
likely due | 3 |
requiring icu | 3 |
lactic acid | 3 |
organ injury | 3 |
stimulating factor | 3 |
city experience | 3 |
general hospital | 3 |
innate immunity | 3 |
published maps | 3 |
disease course | 3 |
worse outcomes | 3 |
cdc criteria | 3 |
old male | 3 |
disease mechanisms | 3 |
potentially infected | 3 |
standardized manner | 3 |
cardiac impairment | 3 |
adhesion molecule | 3 |
patients treated | 3 |
blood group | 3 |
laboratory evaluation | 3 |
children date | 3 |
often associated | 3 |
treated successfully | 3 |
vasopressor support | 3 |
pediatric rheumatology | 3 |
study provides | 3 |
underlying pathophysiology | 3 |
tertiary care | 3 |
chronic diseases | 3 |
pleural effusions | 3 |
regarding mis | 3 |
severe clinical | 3 |
lower gene | 3 |
children required | 3 |
right ventricular | 3 |
canonical kd | 3 |
serum inflammatory | 3 |
postinfectious multisystem | 3 |
pediatric multi | 3 |
block type | 3 |
will provide | 3 |
single centre | 3 |
th pandemic | 3 |
influenza pandemic | 3 |
art review | 3 |
another potential | 3 |
normal systolic | 3 |
clinical teams | 3 |
positive sera | 3 |
imaging characteristics | 3 |
school reopening | 3 |
clinical outcomes | 3 |
results suggest | 3 |
clinically severe | 3 |
compassionate use | 3 |
data become | 3 |
high prevalence | 3 |
children sars | 3 |
type iii | 3 |
emerging reports | 3 |
related inflammatory | 3 |
weeks prior | 3 |
neurological symptoms | 3 |
targeted therapies | 3 |
edta tube | 3 |
detailed descriptions | 3 |
respiratory virus | 3 |
shock requiring | 3 |
pcr positive | 3 |
relatively uncommon | 3 |
increasingly recognized | 3 |
delayed immunological | 3 |
become infected | 3 |
raised concern | 3 |
table compares | 3 |
invasive surgery | 3 |
patients required | 3 |
exact incidence | 3 |
collection cup | 3 |
theatre staff | 3 |
prevalence rate | 3 |
pericardial effusion | 3 |
tiered approach | 3 |
fat stranding | 3 |
psychiatric patients | 3 |
observational studies | 3 |
well established | 3 |
severe pneumonia | 3 |
humoral immune | 3 |
care medical | 3 |
healthier respiratory | 3 |
control clinic | 3 |
possible atypical | 3 |
review clinical | 3 |
treatment protocol | 3 |
viral pneumonia | 3 |
european countries | 3 |
quality biospecimens | 3 |
inflammatory biomarkers | 3 |
january st | 3 |
myocardial inflammation | 3 |
epidemiological features | 3 |
medical informatics | 3 |
neurological disorders | 3 |
prior exposure | 3 |
nih recommends | 3 |
high antibody | 3 |
ventricular ejection | 3 |
reported world | 3 |
kd findings | 3 |
care teams | 3 |
granulocyte colony | 3 |
kd shock | 3 |
active infection | 3 |
blood draws | 3 |
children multisystem | 3 |
room temperature | 3 |
related mis | 3 |
nasopharyngeal swabs | 3 |
kg intravenous | 3 |
mothers infected | 3 |
pediatric septic | 3 |
data collected | 3 |
antifungal therapy | 3 |
tertiary paediatric | 3 |
rare presentation | 3 |
procalcitonin level | 3 |
state department | 3 |
face shield | 3 |
also reported | 3 |
dermatol doi | 3 |
least two | 3 |
ards cases | 3 |
eligible patients | 3 |
questions remain | 3 |
recent reports | 3 |
dragan jankovic | 3 |
strawberry tongue | 3 |
serbia government | 3 |
nasal colonization | 3 |
termed multisystem | 3 |
cytokine levels | 3 |
patients included | 3 |
online version | 3 |
side effects | 3 |
response syndrome | 3 |
medical center | 3 |
statistical analyses | 3 |
remains undetermined | 3 |
profound acute | 3 |
il pg | 3 |
epidemiologic link | 3 |
coronary aneurysm | 3 |
working group | 3 |
obtain informed | 3 |
right lower | 3 |
medical condition | 3 |
kawasaki syndrome | 3 |
pandemic kawasaki | 3 |
tested negative | 3 |
prognostic value | 3 |
patients seen | 3 |
bsl safety | 3 |
questions relating | 3 |
suppression may | 3 |
phenotypes among | 3 |
tissue damage | 3 |
coronavirus pneumonia | 3 |
continuous variables | 3 |
following bsl | 3 |
treatment strategies | 3 |
care clinics | 3 |
disease development | 3 |
proposed mechanisms | 3 |
mis disease | 3 |
two independent | 3 |
findings included | 3 |
include acute | 3 |
continuous data | 3 |
middle east | 3 |
ethics approval | 3 |
intravenous immunoglobulins | 3 |
systemic hyper | 3 |
coronavirus diseases | 3 |
refractory kawasaki | 3 |
psychiatry team | 3 |
laboratory features | 3 |
infection among | 3 |
easysep direct | 3 |
dissecting kawasaki | 3 |
signaling pathways | 3 |
potentially lethal | 3 |
broader age | 3 |
european adhd | 3 |
cutaneous findings | 3 |
highly resilient | 3 |
current covid | 3 |
crp levels | 3 |
positive mothers | 3 |
health advisory | 3 |
commons licence | 3 |
colleagues found | 3 |
recent report | 3 |
may develop | 3 |
clinical approach | 3 |
york approach | 3 |
new cases | 3 |
pandemic pediatric | 3 |
published data | 3 |
frequently used | 3 |
multiracial male | 3 |
symptoms improved | 3 |
direct viral | 3 |
terminal pro | 3 |
mp igg | 3 |
illness onset | 3 |
develop severe | 3 |
step commands | 3 |
arthritis rheumatol | 3 |
studies may | 3 |
complete recovery | 3 |
severe inflammation | 3 |
search strategy | 3 |
hyperinflammatory condition | 3 |
initial diagnosis | 3 |
higher crp | 3 |
biospecimen collection | 3 |
sustained production | 3 |
including acute | 3 |
outcome data | 3 |
laboratory characteristics | 3 |
patients admitted | 3 |
imaging study | 3 |
covid pcr | 3 |
therapeutic strategies | 3 |
infection multisystem | 3 |
may represent | 3 |
pulmonary embolism | 3 |
angiotensinconverting enzyme | 3 |
abdominal ultrasound | 3 |
pediatric centers | 3 |
review date | 3 |
long term | 3 |
geographic region | 3 |
cotton balls | 3 |
remains neutral | 3 |
late gadolinium | 3 |
several case | 3 |
guidance provided | 3 |
cell activation | 3 |
five days | 3 |
typical chest | 3 |
series published | 3 |
bilateral ground | 3 |
hyperinflammatory process | 3 |
may serve | 3 |
children without | 3 |
will present | 3 |
ivig resistance | 3 |
weeks following | 3 |
suspected case | 3 |
rapidly emerging | 3 |
viral testing | 3 |
disease abnormalities | 3 |
infected mother | 3 |
rna extraction | 3 |
systemic juvenile | 3 |
western new | 3 |
two weeks | 3 |
may aid | 3 |
characteristics associated | 3 |
manifestations may | 3 |
helper cells | 3 |
brake activated | 3 |
east respiratory | 3 |
pandemic week | 3 |
airspace opacities | 3 |
pediatric emergency | 3 |
diagnosed children | 3 |
days following | 2 |
medical attention | 2 |
descriptive terminology | 2 |
adults sars | 2 |
vasoactive agents | 2 |
received immunomodulatory | 2 |
adult viral | 2 |
known whether | 2 |
cross protection | 2 |
elevated interleukin | 2 |
tract symptoms | 2 |
collecting high | 2 |
fewer outdoor | 2 |
adverse cardiac | 2 |
units clinical | 2 |
significantly reduced | 2 |
several reported | 2 |
perinatal aspects | 2 |
potential mechanisms | 2 |
typically experience | 2 |
complicating systemic | 2 |
wilcoxon rank | 2 |
prior research | 2 |
stroke nursing | 2 |
rapid prospective | 2 |
illness necessitating | 2 |
phenomenon caused | 2 |
preferred reporting | 2 |
epidemiologic characteristics | 2 |
clinical questions | 2 |
associated inflammatory | 2 |
data will | 2 |
igg positivity | 2 |
economic impacts | 2 |
abnormal echocardiogram | 2 |
scheduling module | 2 |
lr xr | 2 |
academic health | 2 |
italian epicenter | 2 |
class ii | 2 |
paediatric case | 2 |
typically characterized | 2 |
extremely elevated | 2 |
condition may | 2 |
centers including | 2 |
sick contacts | 2 |
preliminary evidence | 2 |
icu patients | 2 |
diagnosed cases | 2 |
multicentre trial | 2 |
ifn responses | 2 |
still scarce | 2 |
pcr tests | 2 |
learned regarding | 2 |
alternative diagnosis | 2 |
patients testing | 2 |
experienced less | 2 |
artery evaluation | 2 |
developed phase | 2 |
mild cases | 2 |
supplies required | 2 |
kawasakilike disease | 2 |
serbia open | 2 |
guidelines group | 2 |
world federation | 2 |
neutrophil rna | 2 |
dilatation compared | 2 |
artery changes | 2 |
table ii | 2 |
cognitive assessment | 2 |
pediatric sepsis | 2 |
major health | 2 |
buffered saline | 2 |
prolonged prothrombin | 2 |
blood urea | 2 |
disease transmission | 2 |
first dose | 2 |
demographic trends | 2 |
responder status | 2 |
lower viral | 2 |
us reported | 2 |
different countries | 2 |
children show | 2 |
blood processing | 2 |
infectious rather | 2 |
complications including | 2 |
emergency room | 2 |
delayed immune | 2 |
one recent | 2 |
olanzapine mg | 2 |
peripheral edema | 2 |
concurrent respiratory | 2 |
related multisystem | 2 |
human subjects | 2 |
positive serologic | 2 |
disease manifestations | 2 |
recent epidemiological | 2 |
chronic neurological | 2 |
myocardial fibrosis | 2 |
dimer levels | 2 |
epidemiologic evidence | 2 |
evolving nature | 2 |
completely novel | 2 |
cardiac chamber | 2 |
african americans | 2 |
children experienced | 2 |
others regarding | 2 |
likely represent | 2 |
well infant | 2 |
neurological diseases | 2 |
picu stay | 2 |
uk cohort | 2 |
demographic information | 2 |
lower hemoglobin | 2 |
disease recognition | 2 |
care treatment | 2 |
suspected appendicitis | 2 |
tested sera | 2 |
different expression | 2 |
physical exam | 2 |
final approval | 2 |
three cases | 2 |
premature atrial | 2 |
also may | 2 |
kg min | 2 |
vasoplegic shock | 2 |
healthcare resources | 2 |
us pediatric | 2 |
defined syndromes | 2 |
disease specialists | 2 |
stress cardiomyopathy | 2 |
female infant | 2 |
without evidence | 2 |
reported covid | 2 |
unlike adults | 2 |
lymphohistiocytosis macrophage | 2 |
pediatric biorepository | 2 |
cell counts | 2 |
viscoelastic testing | 2 |
recommended follow | 2 |
also elevated | 2 |
wall thickening | 2 |
healthcare worker | 2 |
patient demonstrated | 2 |
newborn screening | 2 |
phosphate buffered | 2 |
additional cases | 2 |
mesenteric lymphadenitis | 2 |
hypercoagulable state | 2 |
january th | 2 |
spread worldwide | 2 |
clinical feature | 2 |
diagnostic approach | 2 |
information technology | 2 |
even higher | 2 |
specific inflammatory | 2 |
following illness | 2 |
qt interval | 2 |
ongoing public | 2 |
tier testing | 2 |
important insight | 2 |
many mis | 2 |
characterize mucocutaneous | 2 |
distributive shock | 2 |
may th | 2 |
although significant | 2 |
still needed | 2 |
plasma troponin | 2 |
study kawasaki | 2 |
negative rt | 2 |
case summary | 2 |
may suggest | 2 |
clinical phenotype | 2 |
telomere length | 2 |
analysis systematic | 2 |
biospecimens will | 2 |
neutrophil percent | 2 |
states multisystem | 2 |
regarding pathogenesis | 2 |
prescribed therapy | 2 |
will survive | 2 |
disease patients | 2 |
metaanalysis clinical | 2 |
made initial | 2 |
recent emergence | 2 |
mg iv | 2 |
often require | 2 |
adenovirus type | 2 |
home confinement | 2 |
mucocutaneous eruptions | 2 |
thoracic manifestations | 2 |
treatment options | 2 |
related ards | 2 |
children requiring | 2 |
emergency preparedness | 2 |
acute cor | 2 |
patients manifesting | 2 |
cdc data | 2 |
inflammatory bowel | 2 |
subsequent multisystem | 2 |
etiologic agent | 2 |
processing procedures | 2 |
random forest | 2 |
risk patients | 2 |
splenial lesion | 2 |
assessed independently | 2 |
may improve | 2 |
reported deaths | 2 |
presenting symptoms | 2 |
nine pregnant | 2 |
phone users | 2 |
funding sources | 2 |
providers learn | 2 |
level care | 2 |
small proportion | 2 |
china characteristics | 2 |
hospital settings | 2 |
understanding development | 2 |
aerosolizing procedure | 2 |
lower lobe | 2 |
volume permitting | 2 |
performed using | 2 |
previous reported | 2 |
plasma therapy | 2 |
infections may | 2 |
virus interactions | 2 |
included patients | 2 |
representation comes | 2 |
challenges facing | 2 |
tocilizumab may | 2 |
symptomatic children | 2 |
subsequent infection | 2 |
hvp wy | 2 |
acute febrile | 2 |
required vasopressor | 2 |
following either | 2 |
also common | 2 |
small segmental | 2 |
kd may | 2 |
sectional survey | 2 |
high consensus | 2 |
necessarily indicate | 2 |
answering questions | 2 |
ten case | 2 |
organ transplant | 2 |
pulmonary embolus | 2 |
study population | 2 |
prospective register | 2 |
freezing medium | 2 |
whereas heparin | 2 |
close clinical | 2 |
new evidence | 2 |
states cdc | 2 |
understanding sars | 2 |
observed organ | 2 |
alanine transaminase | 2 |
latin america | 2 |
nrrl kjc | 2 |
immune cells | 2 |
financial relationships | 2 |
dependent difference | 2 |
elevated il | 2 |
spike protein | 2 |
dose iv | 2 |
high procalcitonin | 2 |
paediatric rheumatology | 2 |
aw gv | 2 |
children hospitalized | 2 |
pediatric age | 2 |
therapeutic approaches | 2 |
patient self | 2 |
among adults | 2 |
day course | 2 |
weakness malaise | 2 |
chadox ncov | 2 |
used primarily | 2 |
international expert | 2 |
hcov abs | 2 |
binding sites | 2 |
chronic cardiac | 2 |
numerous reports | 2 |
lorazepam mg | 2 |
short period | 2 |
develop kd | 2 |
novel human | 2 |
adolescents multi | 2 |
johns hopkins | 2 |
delphi process | 2 |
one comorbidity | 2 |
coagulation profile | 2 |
clinical pattern | 2 |
may still | 2 |
xv vuypd | 2 |
mis children | 2 |
icu admissions | 2 |
phenomenon associated | 2 |
favorable results | 2 |
may result | 2 |
asymptomatic sars | 2 |
laparoscopic cases | 2 |
sars coronavirus | 2 |
experience milder | 2 |
initially seemed | 2 |
successful establishment | 2 |
close monitoring | 2 |
mainly due | 2 |
chest pain | 2 |
presenting symptom | 2 |
constitutional higher | 2 |
term multidisciplinary | 2 |
additional studies | 2 |
findings observed | 2 |
lower quadrant | 2 |
will often | 2 |
population continues | 2 |
pulmonary angiography | 2 |
significant increase | 2 |
regarding clinical | 2 |
children represent | 2 |
serum cytokines | 2 |
med doi | 2 |
hospitalization rate | 2 |
important role | 2 |
dose anakinra | 2 |
hyperinflammatory milieu | 2 |
many features | 2 |
persistent fevers | 2 |
cardiac abnormalities | 2 |
describe patients | 2 |
epidemiology study | 2 |
admission lists | 2 |
local availability | 2 |
serial echocardiograms | 2 |
peptide mimetics | 2 |
respiratory machinery | 2 |
pediatric samples | 2 |
enzyme receptors | 2 |
patients also | 2 |
hemodynamic compromise | 2 |
reye syndrome | 2 |
china found | 2 |
heel stick | 2 |
neutralizing titres | 2 |
early recognition | 2 |
younger children | 2 |
testing including | 2 |
pulmonary arterial | 2 |
direct neurotropic | 2 |
children generally | 2 |
pandemic children | 2 |
survey responses | 2 |
showed distinct | 2 |
consent form | 2 |
managing patients | 2 |
one child | 2 |
nasopharyngeal rna | 2 |
published guidelines | 2 |
hcov infection | 2 |
purulent conjunctivitis | 2 |
published series | 2 |
safety guidelines | 2 |
humanized monoclonal | 2 |
average length | 2 |
pandemic clinical | 2 |
significant impact | 2 |
bilateral conjunctivitis | 2 |
eligible participants | 2 |
literature review | 2 |
surfaced describing | 2 |
pathogenic mechanisms | 2 |
subsequent development | 2 |
also recommend | 2 |
report describing | 2 |
flat affect | 2 |
american us | 2 |
antigen test | 2 |
viral rna | 2 |
without mis | 2 |
included hospital | 2 |
novel condition | 2 |
prominent gastrointestinal | 2 |
positivity ranged | 2 |
child adolescent | 2 |
bipolar disorder | 2 |
early consultation | 2 |
case identification | 2 |
whereas others | 2 |
serum igg | 2 |
help guide | 2 |
including patients | 2 |
immunomodulatory medications | 2 |
lysis buffer | 2 |
recently published | 2 |
search yielded | 2 |
hyperinflammation vasodilation | 2 |
reports show | 2 |
viral hyperinflammatory | 2 |
certain clinical | 2 |
mucosal involvement | 2 |
immune effectors | 2 |
full diagnostic | 2 |
alvaro title | 2 |
new case | 2 |
sensitivity analysis | 2 |
mortality due | 2 |
peak incidence | 2 |
ovid medline | 2 |
unique challenges | 2 |
much lower | 2 |
antibodies leading | 2 |
echo findings | 2 |
prior phase | 2 |
bilateral multifocal | 2 |
superantigenic character | 2 |
studies focusing | 2 |
infected persons | 2 |
effects including | 2 |
sterile collection | 2 |
high mortality | 2 |
prominent gi | 2 |
enrolled participants | 2 |
still limited | 2 |
either symptomatic | 2 |
underlying condition | 2 |
children appears | 2 |
system beside | 2 |
experience treating | 2 |
evidence regarding | 2 |
novel severe | 2 |
exact test | 2 |
whereas nonspecific | 2 |
exposure within | 2 |
drive forward | 2 |
febrile mucocutaneous | 2 |
frequent picu | 2 |
including pulmonary | 2 |
cardiac events | 2 |
mildly elevated | 2 |
soluble il | 2 |
infection confirmed | 2 |
therapeutic guidelines | 2 |
based guidelines | 2 |
symptoms including | 2 |
male presented | 2 |
data exist | 2 |
decision making | 2 |
reporting items | 2 |
pathologic mechanisms | 2 |
term consequences | 2 |
serum separator | 2 |
clinically apparent | 2 |
guide development | 2 |
protective response | 2 |
understanding neonatal | 2 |
states pediatric | 2 |
european privacy | 2 |
mary beth | 2 |
involvement including | 2 |
outcomes among | 2 |
relevant papers | 2 |
filtration system | 2 |
proximity tracing | 2 |
positive serological | 2 |
many countries | 2 |
online ahead | 2 |
antibody titres | 2 |
higher lymphocyte | 2 |
reduced number | 2 |
review focuses | 2 |
countries reported | 2 |
cytokine production | 2 |
tcr repertoire | 2 |
close follow | 2 |
wbc counts | 2 |
york metropolitan | 2 |
several potential | 2 |
required additional | 2 |
pharmacologic treatments | 2 |
hospital characteristics | 2 |
coronavirus nl | 2 |
mediated phenomenon | 2 |
postviral immune | 2 |
used including | 2 |
trigger macrophage | 2 |
case incomplete | 2 |
high quality | 2 |
topics study | 2 |
genetic predisposition | 2 |
manifestations compared | 2 |
acetylsalicylic acid | 2 |
drive disease | 2 |
associated coagulopathy | 2 |
new onset | 2 |
np swab | 2 |
adolescent boy | 2 |
reversible splenial | 2 |
increasingly reported | 2 |
mq xb | 2 |
testing may | 2 |
study data | 2 |
cor pulmonale | 2 |
early may | 2 |
hospital mortality | 2 |
corona virus | 2 |
recombinant adenovirus | 2 |
recommendations provided | 2 |
systems involved | 2 |
pneumonia cases | 2 |
mask use | 2 |
critical insight | 2 |
included published | 2 |
rapidly evolving | 2 |
lancet infectious | 2 |
enrollment site | 2 |
subsequent delayed | 2 |
assessed according | 2 |
paxgene rna | 2 |
igg antibodies | 2 |
possible reasons | 2 |
two doses | 2 |
privacy preserving | 2 |
patients classified | 2 |
disease committee | 2 |
chamber size | 2 |
ill adults | 2 |
bacterial infection | 2 |
involved rounds | 2 |
low quality | 2 |
elevated markers | 2 |
igg abs | 2 |
written informed | 2 |
imbalanced host | 2 |
publicly available | 2 |
similar symptoms | 2 |
nem dw | 2 |
novel clinical | 2 |
pediatric studies | 2 |
generalized inflammation | 2 |
pediatric health | 2 |
pathophysiologic mechanisms | 2 |
collect samples | 2 |
proposed clinical | 2 |
sick children | 2 |
regarding options | 2 |
volume october | 2 |
categorical data | 2 |
medical research | 2 |
patient presented | 2 |
electrical conduction | 2 |
neonatal age | 2 |
post infectious | 2 |
cohort multisystem | 2 |
fully elucidated | 2 |
age presenting | 2 |
glass opacity | 2 |
clinical definition | 2 |
mis group | 2 |
common finding | 2 |
paediatric cases | 2 |
old female | 2 |
treat patients | 2 |
cell abnormalities | 2 |
positive test | 2 |
frequently recommended | 2 |
primary care | 2 |
several limitations | 2 |
current state | 2 |
negative sepsis | 2 |
ultrasound scan | 2 |
among adolescents | 2 |
may reflect | 2 |
physical contacts | 2 |
weeks later | 2 |
software platform | 2 |
robust hyperinflammation | 2 |
viral binding | 2 |
colony stimulating | 2 |
room air | 2 |
red cracked | 2 |
bowel diseases | 2 |
first days | 2 |
milder illness | 2 |
severe lv | 2 |
reduced physical | 2 |
frequent respiratory | 2 |
following ivig | 2 |
abnormal coagulation | 2 |
processing technician | 2 |
viral panel | 2 |
following day | 2 |
typically presents | 2 |
left ventricle | 2 |
smaller airways | 2 |
data portal | 2 |
note springer | 2 |
research electronic | 2 |
based therapies | 2 |
protective role | 2 |
potent innate | 2 |
shock epidemiologically | 2 |
unlike previous | 2 |
include presence | 2 |
complete kd | 2 |
software support | 2 |
randomized trials | 2 |
clinical status | 2 |
frequently observed | 2 |
pediatric crohn | 2 |
term memory | 2 |
shock presentation | 2 |
normal range | 2 |
preceding weeks | 2 |
severe inflammatory | 2 |
systemic signs | 2 |
variable among | 2 |
distinct ab | 2 |
like sequences | 2 |
less clinically | 2 |
pilot study | 2 |
pediatric rheumatologists | 2 |
microvascular damage | 2 |
differences observed | 2 |
systemic onset | 2 |
within normal | 2 |
breast milk | 2 |
including erythema | 2 |
series found | 2 |
antibody test | 2 |
diabetes mellitus | 2 |
acutely ill | 2 |
stage severe | 2 |
negative results | 2 |
partners massachusetts | 2 |
existing evidence | 2 |
fold uln | 2 |
possible endothelial | 2 |
mild coronary | 2 |
may impact | 2 |
rajkovic made | 2 |
turn leads | 2 |
rapid spread | 2 |
third researcher | 2 |
lancet child | 2 |
care policy | 2 |
made regarding | 2 |
ab response | 2 |
remain unanswered | 2 |
pulmonary edema | 2 |
series described | 2 |
upper gi | 2 |
refractory cases | 2 |
significant risk | 2 |
higher rate | 2 |
metabolic panel | 2 |
includes fever | 2 |
longitudinal studies | 2 |
hospital evaluation | 2 |
children epidemiology | 2 |
often present | 2 |
mild covid | 2 |
molecular mimicry | 2 |
study reporting | 2 |
lymphocyte count | 2 |
may prevent | 2 |
causal link | 2 |
hospital institutional | 2 |
final guidance | 2 |
treatment modalities | 2 |
infection include | 2 |
potentially life | 2 |
drives development | 2 |
among hospitalized | 2 |
mesenteric lymphadenopathy | 2 |
hopkins university | 2 |
gastrointestinal manifestations | 2 |
involvement similar | 2 |
develop future | 2 |
heart rate | 2 |
reduce mortality | 2 |
require mechanical | 2 |
consensus study | 2 |
specimen transport | 2 |
initial evaluation | 2 |
line therapy | 2 |
cell therapies | 2 |
distinct presentations | 2 |
specific eruption | 2 |
highly infectious | 2 |
study cardiac | 2 |
based study | 2 |
challenge due | 2 |
mis cases | 2 |
simultaneous presence | 2 |
provides evidence | 2 |
one echocardiogram | 2 |
ill icu | 2 |
may affect | 2 |
clinical recommendations | 2 |
findings suggest | 2 |
indiscriminate immunosuppressants | 2 |
recent multicenter | 2 |
without robust | 2 |
two cases | 2 |
values higher | 2 |
similarities yet | 2 |
higher quality | 2 |
recently recovered | 2 |
brazilian research | 2 |
registered protocols | 2 |
additional therapies | 2 |
node swelling | 2 |
months following | 2 |
severe complications | 2 |
typically show | 2 |
institutional biosafety | 2 |
pharmacological treatment | 2 |
comparison among | 2 |
largest pediatric | 2 |
review article | 2 |
treating mis | 2 |
increased susceptibility | 2 |
less consistent | 2 |
sepsis patients | 2 |
negative coronavirus | 2 |
present study | 2 |
cerebral vasculitis | 2 |
current pediatric | 2 |
infected patients | 2 |
meningeal signs | 2 |
following discharge | 2 |
coronary abnormalities | 2 |
caribbean descent | 2 |
alveolar lavage | 2 |
use authorization | 2 |
cases worldwide | 2 |
initial screening | 2 |
disorders may | 2 |
eclinicalmedicine doi | 2 |
upper limit | 2 |
also observed | 2 |
microsoft excel | 2 |
children showed | 2 |
million people | 2 |
data suggest | 2 |
mg subcutaneous | 2 |
used medication | 2 |
second phase | 2 |
allow necessary | 2 |
clinical response | 2 |
hospital days | 2 |
information technologies | 2 |
service information | 2 |
transmissible coronavirus | 2 |
cardiovascular magnetic | 2 |
imaging abnormalities | 2 |
will surely | 2 |
average age | 2 |
last years | 2 |
data extraction | 2 |
old multiracial | 2 |
initial proinflammatory | 2 |
body mass | 2 |
months post | 2 |
coagulation tests | 2 |
high school | 2 |
kobayashi score | 2 |
drove disease | 2 |
critical disease | 2 |
immune memory | 2 |
hyperinflammation phase | 2 |
myocardial necrosis | 2 |
grade fevers | 2 |
additional data | 2 |
preliminary potent | 2 |
present mis | 2 |
nucleotide polymorphisms | 2 |
potential mis | 2 |
regular follow | 2 |
infectious inflammatory | 2 |
home isolation | 2 |
current data | 2 |
international prospective | 2 |
requiring inotropic | 2 |
several weeks | 2 |
future longitudinal | 2 |
dexamethasone may | 2 |
new pediatric | 2 |
agents may | 2 |
control study | 2 |
myocardial changes | 2 |
high rates | 2 |
also important | 2 |
associated cytokine | 2 |
online lessons | 2 |
children following | 2 |
real time | 2 |
findings among | 2 |
recently described | 2 |
aneurysm following | 2 |
china clinical | 2 |
hyperinflammatory syndromes | 2 |
case within | 2 |
mucous membrane | 2 |
patients reported | 2 |
mobile reminder | 2 |
initial echocardiogram | 2 |
electronic health | 2 |
acute presentation | 2 |
red blood | 2 |
providing service | 2 |
mucocutaneous involvement | 2 |
radiographic findings | 2 |
unhealthy lifestyle | 2 |
removing duplicates | 2 |
syndrome may | 2 |
confirmed mis | 2 |
gastrointestinal tract | 2 |
mass index | 2 |
treatment plans | 2 |
immunosuppressive agents | 2 |
antibody response | 2 |
previous studies | 2 |
infection may | 2 |
multiorgan damage | 2 |
secondary infections | 2 |
lumbar puncture | 2 |
hlh may | 2 |
slightly elevated | 2 |
will develop | 2 |
respiratory illnesses | 2 |
supplemental figures | 2 |
neonatal patients | 2 |
differential diagnosis | 2 |
lv function | 2 |
syndrome kawasaki | 2 |
care admissions | 2 |
eye contact | 2 |
active sars | 2 |
logistic regression | 2 |
common presenting | 2 |
phase i | 2 |
met inclusion | 2 |
solid organ | 2 |
paediatr child | 2 |
clinical management | 2 |
following key | 2 |
serological results | 2 |
often used | 2 |
coronavirus infections | 2 |
febrile hyperinflammatory | 2 |
transmembrane conductance | 2 |
known exposure | 2 |
cd cd | 2 |
evolving daily | 2 |
significant disease | 2 |
immunological phenomenon | 2 |
dendritic cells | 2 |
comprehensive review | 2 |
distinct phenomena | 2 |
delayed finding | 2 |
treatments provided | 2 |
reduce social | 2 |
international travel | 2 |
nonspecific markers | 2 |
future understanding | 2 |
press peer | 2 |
children often | 2 |
subjective fever | 2 |
moderate covid | 2 |
provided clinical | 2 |
segmental pulmonary | 2 |
factors may | 2 |
collection study | 2 |
minimal spontaneous | 2 |
pandemic weeks | 2 |
smatteo covid | 2 |
yet unknown | 2 |
ct scan | 2 |
compares common | 2 |
highly vulnerable | 2 |
initial criteria | 2 |
metropolitan area | 2 |
term complications | 2 |
shorter length | 2 |
studies involving | 2 |
responded well | 2 |
higher il | 2 |
medical databases | 2 |
elevated proinflammatory | 2 |
included open | 2 |
least organ | 2 |
just like | 2 |
infectious etiologies | 2 |
ongoing follow | 2 |
emerging syndrome | 2 |
patient showed | 2 |
serial laboratory | 2 |
outbreak will | 2 |
cell function | 2 |
symptomatic individuals | 2 |
regular intervals | 2 |
targeted interventions | 2 |
killer cells | 2 |
various pathogens | 2 |
current pandemic | 2 |
current recommendations | 2 |
angiotensin system | 2 |
descriptive study | 2 |
cardiovascular surgery | 2 |
individual patients | 2 |
existing comorbidities | 2 |
large cohort | 2 |
obstetric covid | 2 |
phase iii | 2 |
treatment approach | 2 |
patient met | 2 |
edta anticoagulant | 2 |
primarily respiratory | 2 |
research studies | 2 |
including fever | 2 |
infants aged | 2 |
adolescent health | 2 |
elevated procalcitonin | 2 |
endemic seasonal | 2 |
many questions | 2 |
genetic variations | 2 |
research coordinators | 2 |
associated multi | 2 |
fibrosis transmembrane | 2 |
endemic countries | 2 |
analysis comparing | 2 |
ten patients | 2 |
children hyperinflammatory | 2 |
inflammatory disorders | 2 |
myocardial function | 2 |
breathing difficulties | 2 |
mild encephalopathy | 2 |
neutralizing capability | 2 |
unit admission | 2 |
regarding treatments | 2 |
single dose | 2 |
patients respond | 2 |
centers world | 2 |
clinical significance | 2 |
multicentre observational | 2 |
informatics support | 2 |
control clinics | 2 |
perceived risk | 2 |
similar features | 2 |
series highlights | 2 |
yet fully | 2 |
epidemiological studies | 2 |
cardiology working | 2 |
children also | 2 |
kidney failure | 2 |
developed countries | 2 |
important implications | 2 |
compared results | 2 |
children experience | 2 |
largely spared | 2 |
higher percentage | 2 |
child abuse | 2 |
multicenter cohort | 2 |
screening clinics | 2 |
following suspected | 2 |
may become | 2 |
date review | 2 |
immune systems | 2 |
urea nitrogen | 2 |
using easysep | 2 |
surgical practice | 2 |
mortality rates | 2 |
grade fever | 2 |
cochrane library | 2 |
creatinine kinase | 2 |
similar treatment | 2 |
known covid | 2 |
compared using | 2 |
scheduling tool | 2 |
almost always | 2 |
one case | 2 |
nk cell | 2 |
age children | 2 |
asymptomatic infection | 2 |
adverse events | 2 |
dysfunction may | 2 |
modified delphi | 2 |
western europe | 2 |
differences may | 2 |
specific cytokines | 2 |
anonymous voting | 2 |
clinical evaluation | 2 |
ace receptor | 2 |
cell response | 2 |
scientific papers | 2 |
reaction testing | 2 |
widely used | 2 |
corrected qt | 2 |
pediatric cohorts | 2 |
sole descriptor | 2 |
sinus tachycardia | 2 |
serum creatinine | 2 |
novel pathogen | 2 |
rna lysis | 2 |
relatively broad | 2 |
enrolled subjects | 2 |
also develop | 2 |
substantial proportion | 2 |
individual patient | 2 |
years age | 2 |
may occur | 2 |
elevated bnp | 2 |
based dashboard | 2 |
interactive web | 2 |
several speculations | 2 |
first admission | 2 |
ultralow particulate | 2 |
cardiac support | 2 |
reference standard | 2 |
electronic data | 2 |
cardiac evaluation | 2 |
open access | 2 |
therapeutic targets | 2 |
subsequent case | 2 |
management date | 2 |
high mis | 2 |
medical records | 2 |
management covid | 2 |
experience clinical | 2 |
annual well | 2 |
meet mis | 2 |
modulating drugs | 2 |
proinflammatory response | 2 |
neutrophil isolation | 2 |
hospital admission | 2 |
including conjunctivitis | 2 |
less frequency | 2 |
first time | 2 |
methylprednisolone mg | 2 |
adult inpatients | 2 |
reports suggested | 2 |
therapies will | 2 |
shock state | 2 |
ctl patients | 2 |
two series | 2 |
exhibited profound | 2 |
also received | 2 |
volume resuscitation | 2 |
whereas intercellular | 2 |
reverse transcription | 2 |
case describes | 2 |
rarely seen | 2 |
identified children | 2 |
emergency surgery | 2 |
ards pattern | 2 |
polymorphous rash | 2 |
inflammatory responses | 2 |
future research | 2 |
degree atrioventricular | 2 |
children develop | 2 |
china covid | 2 |
frequently requiring | 2 |
neutralization assay | 2 |
hyper inflammatory | 2 |
necessary comparative | 2 |
first described | 2 |
persistent elevation | 2 |
one record | 2 |
manifestations including | 2 |
whole study | 2 |
calculated using | 2 |
specifically nk | 2 |
severe gi | 2 |
preserving proximity | 2 |
ards development | 2 |
infectious workup | 2 |
gov health | 2 |
pulmonary manifestations | 2 |
human neutrophil | 2 |
cytokines elevations | 2 |
central line | 2 |
syndrome complicating | 2 |
searched four | 2 |
considered positive | 2 |
steroid treatment | 2 |
recent data | 2 |
radiological characteristics | 2 |
common among | 2 |
disease association | 2 |
force also | 2 |
showed increased | 2 |
higher mortality | 2 |
autoimmune encephalitis | 2 |
among others | 2 |
venous thrombosis | 2 |
male gender | 2 |
blood gas | 2 |
csf studies | 2 |
pediatric hospitals | 2 |
pandemic progresses | 2 |
include prolonged | 2 |
blood donors | 2 |
median score | 2 |
human services | 2 |
protease inhibitor | 2 |
mcg kg | 2 |
screening evaluation | 2 |
clinical patterns | 2 |
key differences | 2 |
empiric antibiotics | 2 |
proinflammatory state | 2 |
flow nasal | 2 |
although lv | 2 |
interferon responses | 2 |
us centers | 2 |
potential risk | 2 |
transmission dynamics | 2 |
detect sars | 2 |
related differences | 2 |
hematologic abnormalities | 2 |
statements accompanied | 2 |
infection characterized | 2 |
vascular disease | 2 |
five states | 2 |
help determine | 2 |
lower percentage | 2 |
including hypercoagulable | 2 |
group comprised | 2 |
echocardiogram performed | 2 |
understanding mis | 2 |
hiv infection | 2 |
blood volumes | 2 |
response drove | 2 |
affected family | 2 |
subcutaneous every | 2 |
safety precautions | 2 |
novel phenomenon | 2 |
may act | 2 |
lips tests | 2 |
described mis | 2 |
mechanistic understanding | 2 |
ct pulmonary | 2 |
adhd guidelines | 2 |
highly recommended | 2 |
robotic surgery | 2 |
symptoms concerning | 2 |
adaptive system | 2 |
neurologic symptoms | 2 |
efficient response | 2 |
anticoagulation therapy | 2 |
health centers | 2 |
times higher | 2 |
inflammatory parameters | 2 |
infectious immune | 2 |
lopinavir ritonavir | 2 |
children clinical | 2 |
pandemic covid | 2 |
patchy lesions | 2 |
periorbital edema | 2 |
european society | 2 |
clin dermatol | 2 |
troponin elevation | 2 |
years hospitalized | 2 |
lv ejection | 2 |
concomitant covid | 2 |
spontaneous movement | 2 |
cells tube | 2 |
tier screening | 2 |
syndrome incidence | 2 |
laboratory analyses | 2 |
asymptomatic covid | 2 |
bcg vaccine | 2 |
intercellular adhesion | 2 |
intrauterine vertical | 2 |
pericardial diseases | 2 |
cardiovascular abnormalities | 2 |
million cells | 2 |
specimen cup | 2 |
pain diarrhea | 2 |
diminished ventricular | 2 |
multidisciplinary follow | 2 |
rare complication | 2 |
prevent sars | 2 |
two studies | 2 |
chronic pulmonary | 2 |
younger age | 2 |
male predominance | 2 |
nucleic acid | 2 |
polymorphic rash | 2 |
cytokines including | 2 |
since mid | 2 |
pulmonary vascular | 2 |
infection appears | 2 |
declared covid | 2 |
series reported | 2 |
potential protective | 2 |
rheumatology clinical | 2 |
cardiac damage | 2 |
biorepository included | 2 |
younger patients | 2 |
lung disease | 2 |
cell responses | 2 |
although mis | 2 |
status exam | 2 |
reasonable request | 2 |
also similar | 2 |
one report | 2 |
severe right | 2 |